China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.